In contrast to controlled clinical trials, findings of preclinical studies are not available. The road from laboratory discovery to usable therapy is still long and windy. Many preclinical studies have not been replicated by the pharmaceutical sector, the costs of clinical trials are rising, and many trials fail due to insufficient animal model evidence. To improve cross-talk between scientists and to develop rational strategies to move therapies into the clinic, scientists are going to be invited to register their experiments. The proposed registration and availability of preclinical research findings, published in the June 2012 issue of Nature Biotechnology by Kimmelman and Anderson, would facilitate a clinical translation process that would benefit the scientific community. In particular, to support clinical trial development programs, they propose the design and registration of controlled in vivo animal studies testing toxicity, toxicology, and disease response with a similar structure to controlled clinical trials.
Editor-in-Chief:
Co-Editor:
Managing Editor
Associate Editors:
Section Editors:
Ad-hoc Editors:
Editor Emeritus: